August 2012
-
Akela Pharma has announced completion of a private placement totaling $2,310,000 that it will use primarily for expansion of spray drying and hot melt extrusion capabilities at its subsidiary, PharmaForm. Although PharmaForm specializes in solid… Read more . . .
-
Almirall has announced the filing of new applications for its Sativex endocannabinoid oromucosal spray for the treatment of spasticity in multiple sclerosis in ten additional countries: Belgium, Finland, Iceland, Ireland, Luxemburg, the Netherlands, Norway, Poland,… Read more . . .
-
Team Consulting has announced the opening of its new Respiratory Physics Laboratory at the company headquarters in Ickleton, Cambridgeshire, UK. Recent hire Mark Shepherd will manage the cGMP laboratory. “In recent years we have worked… Read more . . .
-
The FDA has accepted an Investigational New Drug application (IND) submitted by San Diego, CA pharmaceutical company Neurelis. The company is cleared to begin clinical trials for the development of its NRL-1 intranasal diazepam for… Read more . . .
-
According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), American pharmaceutical companies have 54 COPD medications in their pipelines. The list of drugs in development includes all dosage forms, including… Read more . . .
-
The new Medicon Valley Inhalation Consortium (MVIC) includes seven inhalation technology companies located in the Skåne-Copenhagen region of Scandinavia. According to the consortium, it “will work to globally promote Medicon Valley as an international center… Read more . . .
-
Bedford Laboratories has announced a national (US) voluntary product recall of acetylcysteine solution manufactured for Roxane Laboratories. The recall was initiated on December 20, 2011 due to a visible glass particle in a vial of… Read more . . .
-
Prosonix has announced the appointment of Geoff Down to the newly-created position of Chief Medical Officer, effective immediately. Down, who has extensive experience in clinical development and has served various roles, some as a consultant… Read more . . .
-
According to OptiNose, it filed an investigational new drug (IND) application for an intranasal sumatriptan product with the US FDA in December, 2011, and the FDA has given OptiNose permission to proceed. The company now… Read more . . .
-
Discovery Laboratories has announced that the FDA has approved the Afectair device for marketing in the US, and the company plans a launch later this year. The company describes Afectair as “a proprietary patient interface… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland